POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES
Domain expertise, global resource, long-term capital
PORTFOLIO NEWS
Proceeds to fund development of novel and best-in-class therapeutics for eye diseasesCharles...November 9, 2020 – RemeGen, a Yantai, Shandong-based biotech, debuted on Hong Kong Stock Exchange...SUZHOU and SHANGHAI, China, October 28, 2020 -- Gracell Biotechnologies Inc. (“Gracell”), a...BEIJING, CHINA and CAMBRIDGE, MASSACHUSETTS, US – (October 13, 2020) – EdiGene, Inc., which...InventisBio, a clinical stage biotech company dedicated to the research and development of...09/06/2020 – Singleron Biotechnologies, a Chinese start-up developing high-throughput single-cell...2020年8月29日August 28, 2020, Shanghai—Sansure Biotech was listed and started trading on the STAR market of...- In an oversubscribed round, top-tier investors provide significant financial resources to...More Posts
Company
Shanghai
Room2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.
Hong Kong
Unit 902-904, Two ChinaChem Central, 26 Des Voeux Road Central, Hong Kong
US
2730 Sand Hill Road, Suite 130, Menlo Park, CA
All Posts
×
LillyAsiaVentures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
http://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png